Display options
Cite
Miljković S, Smajlović D, Tirić Campara M, et al. The first comparative double-blind trial on efficacy and safety of ergotamine based five-component combination and sumatriptan in migraine without aura. Hippokratia. 2018;22(1):17-22
Miljković, S., Smajlović, D., Tirić Campara, M., Jurina, R., Duranović Vinković, L., Janković, S. M., Begović, B., & Ćeranić, M. (2018). The first comparative double-blind trial on efficacy and safety of ergotamine based five-component combination and sumatriptan in migraine without aura. Hippokratia, 22(1), 17-22.
Miljković, S, et al. "The first comparative double-blind trial on efficacy and safety of ergotamine based five-component combination and sumatriptan in migraine without aura." Hippokratia vol. 22,1 (2018): 17-22.
Miljković S, Smajlović D, Tirić Campara M, Jurina R, Duranović Vinković L, Janković SM, Begović B, Ćeranić M. The first comparative double-blind trial on efficacy and safety of ergotamine based five-component combination and sumatriptan in migraine without aura. Hippokratia. 2018 Jan-Mar;22(1):17-22. PMID: 31213753; PMCID: PMC6528700.
Copy Download .nbib Format: NLM
Share it on

Hippokratia. 2018 Jan-Mar;22(1):17-22.

The first comparative double-blind trial on efficacy and safety of ergotamine based five-component combination and sumatriptan in migraine without aura.

Hippokratia

S Miljković, Dz Smajlović, M Tirić Campara, R Jurina, L Duranović Vinković, S M Janković, B Begović, M Ćeranić

Affiliations

  1. Department of Neurology, University Clinical Center Banja Luka, Bosnia and Herzegovina.
  2. Department of Neurology, University Clinical Center Tuzla, Bosnia and Herzegovina.
  3. Department of Neurology, University Clinical Center Sarajevo, Bosnia and Herzegovina.
  4. Department of Neurology, University Clinical Hospital Mostar, Bosnia and Herzegovina.
  5. Department of Neurology, Cantonal Hospital "Dr. Safet Muji?" Mostar (Regional Medical Center), Bosnia and Herzegovina.
  6. Faculty of Medical Science, University of Kragujevac, Serbia.
  7. Society for Pharmacoeconomics and Outcomes Research in Bosnia and Herzegovina, ISPOR Regional Chapter, Bosnia and Herzegovina.
  8. Bosnalijek dd, Sarajevo, Bosnia and Herzegovina.

PMID: 31213753 PMCID: PMC6528700

Abstract

BACKGROUND: Dihydroergotamine or ergotamine are the most effective preparations for aborting acute attacks of migraine without aura.

OBJECTIVE: The aim of our study was to compare the efficacy and safety of ergotamine based five-component drug combination and sumatriptan in the treatment of moderate to severe acute attacks of migraine without aura.

METHODS: The study was designed as a randomized, double-blind, double-dummy, placebo-controlled, parallel arm, multi-center clinical trial. The enrolled patients having migraine without aura were randomized to one of the study arms, ergotamine based five-component drug combination or sumatriptan.

RESULTS: In total, 201 patients were randomized to one of the treatment arms. Higher percentage of patients was completely free of the headache two hours after dose administration in the ergotamine-based medication group compared to the sumatriptan group, regardless whether all (51.12 % vs 33.70 %) or only repeated attacks were taken into account (50.91 % vs 23.73 %); the salvage therapy (diclofenac) utilization rate was also lower in the ergotamine-based medication group (relative risk 0.61). Photophobia, phonophobia, and osmophobia were reversed more frequently in the ergotamine-based medication group (51.12 % vs 33.70 %), and failure to abort an attack of the migraine without aura occurred more frequently in the group treated with sumatriptan (1.1 % vs 4.9 %). The headache intensity two hours after ingestion of the study medication increased more frequently with sumatriptan, while other adverse events were rare in both groups.

CONCLUSIONS: This study demonstrated higher efficacy and similar safety of ergotamine based fixed drug combination in comparison to sumatriptan, when used in the treatment of an acute attack of the migraine. HIPPOKRATIA 2018, 22(1): 17-22.

Keywords: efficacy; ergotamine based fixed drug combinations; migraine without aura; safety; sumatriptan

Conflict of interest statement

The authors declare no conflict of interest in regard to contents of this article.

References

  1. Cephalalgia. 2000 Nov;20(9):765-86 - PubMed
  2. CNS Drugs. 2005;19(7):635-42 - PubMed
  3. Eur J Neurol. 2007 Mar;14(3):269-75 - PubMed
  4. J AOAC Int. 2007 Jan-Feb;90(1):94-101 - PubMed
  5. Expert Rev Neurother. 2007 Sep;7(9):1105-20 - PubMed
  6. Headache. 2008 Apr;48(4):601-5 - PubMed
  7. P T. 2008 Jul;33(7):404-16 - PubMed
  8. Eur Neuropsychopharmacol. 2011 Oct;21(10):718-79 - PubMed
  9. Headache. 2012 Apr;52(4):707-14 - PubMed
  10. Neurol Sci. 2012 May;33 Suppl 1:S193-8 - PubMed
  11. Ther Adv Drug Saf. 2014 Apr;5(2):87-99 - PubMed
  12. Headache. 2015 Jan;55(1):3-20 - PubMed
  13. Postgrad Med. 2016 Jun;128(5):523-37 - PubMed
  14. Cochrane Database Syst Rev. 2016 Apr 20;4:CD008541 - PubMed
  15. Springerplus. 2016 May 17;5:637 - PubMed
  16. Neurol Clin. 2016 Nov;34(4):849-861 - PubMed
  17. N Engl J Med. 2017 Aug 10;377(6):553-561 - PubMed
  18. Acta Neurol Taiwan. 2017 Jun 15;26(2):78-96 - PubMed
  19. Lancet. 2018 Mar 31;391(10127):1315-1330 - PubMed
  20. Curr Pain Headache Rep. 2018 Mar 19;22(4):23 - PubMed
  21. ZFA (Stuttgart). 1983 Feb 10;59(4):215-8 - PubMed

Publication Types